{"entity":{"id":"nct07069595","kind":"trial","name":"PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease","aka":["PREDICT-RD"],"tldr":"A phase 2 trial of datopotamab deruxtecan in triple-negative breast cancer, run by UNC Lineberger Comprehensive Cancer Center, now recruiting.","summary":"PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease is a phase 2, interventional study registered as NCT07069595 by UNC Lineberger Comprehensive Cancer Center, with a registry enrolment figure of 78 participants, started 2026-02-26 and due to reach its primary completion in 2031-11-01. Interventions recorded: Datopotamab deruxtecan; Circulating tumor DNA (ctDNA) testing. Conditions listed: Breast Cancer; Residual Disease; Triple Negative Breast Cancer (TNBC); Stage II/III. Triple-negative eligibility wording from the registry: \"* Histological confirmation of TNBC defined by ER/PR \\<10%, HER2 0-1+ by IHC or 2+ by IHC and fluorescence in situ hybridization (FISH) negative\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07069595","url":"https://clinicaltrials.gov/study/NCT07069595"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["datopotamab-deruxtecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07069595","phase":"2","setting":"PREDICT-RD: Postoperative Molecular Residual Disease by ctDNA Surveillance in TNBC With Residual Disease","sponsor":"UNC Lineberger Comprehensive Cancer Center","enrolled":78,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07069595/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}